160 related articles for article (PubMed ID: 8516217)
1. Morphometric study of the bone marrow in polycythemia vera following interferon-alpha therapy.
Franco V; Florena AM; Aragona F; Campesi G
Pathol Res Pract; 1993 Feb; 189(1):52-7. PubMed ID: 8516217
[TBL] [Abstract][Full Text] [Related]
2. Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies.
Ellis JT; Peterson P; Geller SA; Rappaport H
Semin Hematol; 1986 Apr; 23(2):144-55. PubMed ID: 3704666
[TBL] [Abstract][Full Text] [Related]
3. The value of bone marrow histology in differentiating between early stage Polycythemia vera and secondary (reactive) Polycythemias.
Thiele J; Kvasnicka HM; Zankovich R; Diehl V
Haematologica; 2001 Apr; 86(4):368-74. PubMed ID: 11325641
[TBL] [Abstract][Full Text] [Related]
4. Polycythaemia vera: bone marrow histopathology under treatment with interferon, hydroxyurea and busulphan.
Kreft A; Nolde C; Büsche G; Buhr T; Kreipe H; Georgii A
Eur J Haematol; 2000 Jan; 64(1):32-41. PubMed ID: 10680703
[TBL] [Abstract][Full Text] [Related]
5. Bone marrow features of diagnostic impact in erythrocytosis.
Thiele J; Kvasnicka HM; Diehl V
Ann Hematol; 2005 Jun; 84(6):362-7. PubMed ID: 15803315
[TBL] [Abstract][Full Text] [Related]
6. [Use of interferon in the treatment of chronic myeloproliferative disorders].
Robak T
Acta Haematol Pol; 1992; 23(2 Suppl 1):30-7. PubMed ID: 1488870
[TBL] [Abstract][Full Text] [Related]
7. Pegylated interferon for the treatment of early myelofibrosis: correlation of serial laboratory studies with response to therapy.
O'Neill C; Siddiqi I; Brynes RK; Vergara-Lluri M; Moschiano E; O'Connell C
Ann Hematol; 2016 Apr; 95(5):733-8. PubMed ID: 26961933
[TBL] [Abstract][Full Text] [Related]
8. Polycythemia rubra vera versus secondary polycythemias. A clinicopathological evaluation of distinctive features in 199 patients.
Thiele J; Kvasnicka HM; Muehlhausen K; Walter S; Zankovich R; Diehl V
Pathol Res Pract; 2001; 197(2):77-84. PubMed ID: 11261821
[TBL] [Abstract][Full Text] [Related]
9. Megakaryopoiesis and myelofibrosis in chronic myeloid leukemia after allogeneic bone marrow transplantation: an immunohistochemical study of 127 patients.
Thiele J; Kvasnicka HM; Beelen DW; Flucke U; Spoer C; Paperno S; Leder LD; Schaefer UW
Mod Pathol; 2001 Feb; 14(2):129-38. PubMed ID: 11235904
[TBL] [Abstract][Full Text] [Related]
10. Complex karyotype in a polycythemia vera patient with a novel SETD1B/GTF2H3 fusion gene.
Tiziana Storlazzi C; Pieri L; Paoli C; Daniele G; Lasho T; Tefferi A; Vannucchi AM
Am J Hematol; 2014 Apr; 89(4):438-42. PubMed ID: 24382738
[TBL] [Abstract][Full Text] [Related]
11. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group.
Michiels JJ; Juvonen E
Semin Thromb Hemost; 1997; 23(4):339-47. PubMed ID: 9263350
[TBL] [Abstract][Full Text] [Related]
12. The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera.
Abdulkarim K; Ridell B; Johansson P; Kutti J; Safai-Kutti S; Andréasson B
Eur J Haematol; 2011 Feb; 86(2):148-55. PubMed ID: 21059102
[TBL] [Abstract][Full Text] [Related]
13. The bone marrow in polycythemia vera.
Ellis JT; Peterson P
Pathol Annu; 1979; 14 Pt 1():383-403. PubMed ID: 390480
[TBL] [Abstract][Full Text] [Related]
14. Effects of chemotherapy (busulfan-hydroxyurea) and interferon-alfa on bone marrow morphologic features in chronic myelogenous leukemia. Histochemical and morphometric study on sequential trephine biopsy specimens with special emphasis on dynamic features.
Thiele J; Kvasnicka HM; Schmitt-Graeff A; Bundschuh S; Biermann T; Roessler G; Wasmus M; Diehl V; Zankovich R; Schaefer HE
Am J Clin Pathol; 2000 Jul; 114(1):57-65. PubMed ID: 10884800
[TBL] [Abstract][Full Text] [Related]
15. Evolution of bone marrow fibrosis and stromal antigenic expression in chronic myeloid leukemia on alpha interferon and Ara-C therapy.
Straetmans N; Ma DD; Nevell DF; Arthur C
Hematopathol Mol Hematol; 1996; 10(4):213-22. PubMed ID: 9042664
[TBL] [Abstract][Full Text] [Related]
16. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
[TBL] [Abstract][Full Text] [Related]
17. The role of beta-catenin in chronic myeloproliferative disorders.
Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
[TBL] [Abstract][Full Text] [Related]
18. The role of alpha-interferon in essential thrombocythaemia, polycythaemia vera and myelofibrosis with myeloid metaplasia (MMM): a concise update.
Sacchi S
Leuk Lymphoma; 1995 Sep; 19(1-2):13-20. PubMed ID: 8574158
[TBL] [Abstract][Full Text] [Related]
19. [Megakaryocytopoiesis in myeloproliferative disorders].
Podolak-Dawidziak M
Acta Haematol Pol; 1992; 23(2 Suppl 1):19-22. PubMed ID: 1488868
[No Abstract] [Full Text] [Related]
20. Contribution of bone marrow biopsy in the diagnosis and prognosis of polycythemia vera.
de Mascarel A
Nouv Rev Fr Hematol (1978); 1994 Apr; 36(2):165-6. PubMed ID: 8036134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
